Analysis: How New Approval Standards May Spur Chinese Covid Pills

(Blue View) — Chinese drugmakers may soon roll out more treatments for Covid-19 after health regulators moved the goal posts last week for determining whether a therapy works.

The National Medical Products Administration (NMPA), the gatekeeper for approving new drugs in China, ruled that the goal in clinical trials of new Covid medicines can be to demonstrate a simple improvement of symptoms. The previous target was a reduction of hospitalizations or fatalities.